MD Anderson Cancer: Targeted Therapy Pralsetinib Safely and Effectively Treats Lung and Thyroid Cancers With RET Alterations
June 10, 2021
June 10, 2021
HOUSTON, Texas, June 10 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on June 9, 2021:
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered . . .
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered . . .